New heart failure drug candidate passes first safety hurdle in obese volunteers
Disease control
Completed
This early-phase trial tested a single dose of the investigational drug THRV-1268 in 16 healthy obese adults to see if it is safe and tolerable. The drug is being developed as a potential treatment for heart failure. The study did not test effectiveness, only safety and how the d…
Phase: PHASE1 • Sponsor: Thryv Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC